HK1003106A1 - Method for inhibiting pulmonary oxygen toxicity - Google Patents

Method for inhibiting pulmonary oxygen toxicity

Info

Publication number
HK1003106A1
HK1003106A1 HK98102152A HK98102152A HK1003106A1 HK 1003106 A1 HK1003106 A1 HK 1003106A1 HK 98102152 A HK98102152 A HK 98102152A HK 98102152 A HK98102152 A HK 98102152A HK 1003106 A1 HK1003106 A1 HK 1003106A1
Authority
HK
Hong Kong
Prior art keywords
oxygen toxicity
inhibiting pulmonary
pulmonary oxygen
inhibiting
toxicity
Prior art date
Application number
HK98102152A
Other languages
English (en)
Inventor
Craig D Wegner
L Gordon Letts
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of HK1003106A1 publication Critical patent/HK1003106A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK98102152A 1991-04-03 1998-03-16 Method for inhibiting pulmonary oxygen toxicity HK1003106A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67987091A 1991-04-03 1991-04-03

Publications (1)

Publication Number Publication Date
HK1003106A1 true HK1003106A1 (en) 1998-10-09

Family

ID=24728710

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98102152A HK1003106A1 (en) 1991-04-03 1998-03-16 Method for inhibiting pulmonary oxygen toxicity

Country Status (13)

Country Link
US (1) US5310551A (xx)
EP (1) EP0507187B1 (xx)
JP (1) JP3228548B2 (xx)
AT (1) ATE145827T1 (xx)
AU (1) AU655459B2 (xx)
CA (1) CA2064604C (xx)
DE (1) DE69215568T2 (xx)
DK (1) DK0507187T3 (xx)
ES (1) ES2094837T3 (xx)
GR (1) GR3022578T3 (xx)
HK (1) HK1003106A1 (xx)
NZ (1) NZ242192A (xx)
ZA (1) ZA922408B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
US20190290623A1 (en) * 2018-03-26 2019-09-26 The Unites States of America Represented by the Secretary of Navy Use of tiotropium bromide to prevent pulmonary oxygen toxicity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
DK0387701T3 (da) * 1989-03-09 1992-12-07 Boehringer Ingelheim Pharma Anvendelse af intercellulære adhæsionsmolekyler samt deres bindende ligander ved behandling af astma

Also Published As

Publication number Publication date
EP0507187B1 (en) 1996-12-04
CA2064604C (en) 2007-07-10
AU1398692A (en) 1992-10-08
DE69215568T2 (de) 1997-05-15
JP3228548B2 (ja) 2001-11-12
DE69215568D1 (de) 1997-01-16
US5310551A (en) 1994-05-10
JPH05255103A (ja) 1993-10-05
ZA922408B (en) 1992-12-30
DK0507187T3 (da) 1997-04-07
ATE145827T1 (de) 1996-12-15
EP0507187A1 (en) 1992-10-07
AU655459B2 (en) 1994-12-22
CA2064604A1 (en) 1992-10-04
GR3022578T3 (en) 1997-05-31
ES2094837T3 (es) 1997-02-01
NZ242192A (en) 1997-06-24

Similar Documents

Publication Publication Date Title
US4997657B1 (en) Method for improving skin smoothness.
MX9700082A (es) Composicion que consiste de morfina, polipirrolidona y oxido de polialquileno.
DE69232480T2 (de) Beatmungsgerät zur Erzeugung von kontinuierlichem positiven Atemwegdruck (CPAP)
DE69420412T2 (de) Therapeutisches inhalationspräparat
IL98258A0 (en) Composition for treating impotence containing doxazosin,amlodipine,or u.k.52,046
AU2415888A (en) A method for preventing blood coaguli from being formed in the extra-body circuit of dialysis apparatus and composition useful therefor
GR3022578T3 (en) Method for inhibiting pulmonary oxygen toxicity
AU7777794A (en) Melatonin derivatives for use in treating sleep disorders
SG49239A1 (en) Amylin and possibly insulin containing composition for the treatment of aneroxia and related states
AU695825B2 (en) Medical gas mixture
EP0401262A4 (en) 24r-scymnol, and preparation and use thereof
AU7719591A (en) Therapeutic agent
AU613510B2 (en) Use of zofenopril for the treatment of rheumatoid arthritis
AU7719491A (en) Therapeutic compound
ZA9244B (en) Antidepressant
GR3005889T3 (xx)
AU1282592A (en) Method for treatment for neuro-muscular incontinence
UA38888A (uk) Спосіб лікування хронічного вірусного гепатиту
LTIP1976A (en) Compositions for inhalation, method for priparing the same, using the same and inhaler
UA10074A (uk) Спосіб профілактики інгаляційних отруєнь нітрогазами
CS551390A3 (en) Low-pressure source for lung artificial respiration instruments
EP0661541A3 (de) Verfahren zur Herstellung langzeitstabiler klarer Seren.

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20120323